Injectable HIV treatment trial for people with unsuppressed virus
Treatments studied
Part of Infections clinical trials.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have had HIV for at least 12 months.
- Your most recent viral load test must be 200 or higher, even if you've been taking your HIV pills irregularly.
- You must weigh at least 35 kilograms (about 77 pounds).
- You must be willing to get injections in the buttocks and stay in touch with the study team.
- You cannot have known resistance to the study drugs cabotegravir or rilpivirine.
- You cannot be pregnant, planning pregnancy, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
This study looks at whether two HIV medicines given as injections every 4 weeks—cabotegravir and rilpivirine—are safe and effective for pregnant women with HIV who have an undetectable viral load. The goal is to help pregnant people with HIV stay healthy and reduce the risk of passing HIV to their baby.
This study looks at how people living with HIV feel (quality of life) and how well their virus is controlled after they finish a long-acting injectable treatment with cabotegravir and rilpivirine. It's a follow-up to see if this easier treatment helps people stay healthy and feel better.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study looks at switching people with HIV from daily or regular oral medicine to long-acting injections (cabotegravir plus rilpivirine). It may help those who are well-controlled on current therapy who prefer injections and can safely take this combination.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.